David Miller, MD, PhD

Panelists discuss how emerging nonsurgical options such as hedgehog pathway inhibitors, immune checkpoint inhibitors, and photodynamic therapy are expanding treatment possibilities for patients with advanced basal cell carcinoma (BCC), particularly for those unsuitable for or unresponsive to traditional surgical interventions.

Panelists discuss how factors such as tumor size, location, patient age, and overall health guide the decision between surgical excision and nonsurgical treatments such as topical therapies or radiation for managing basal cell carcinoma (BCC) effectively.

Panelists discuss how a collaborative approach involving dermatologists, oncologists, and surgeons can optimize treatment outcomes and quality of life for patients with basal cell carcinoma through personalized, comprehensive care plans.